- Home
- CHN vs SWKH Comparison
CHN vs SWKH Comparison
Compare CHN & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHN
- SWKH
- Stock Information
- Founded
- CHN 1992
- SWKH 1996
- Country
- CHN United States
- SWKH United States
- Employees
- CHN N/A
- SWKH N/A
- Industry
- CHN Investment Managers
- SWKH Diversified Financial Services
- Sector
- CHN Finance
- SWKH Finance
- Exchange
- CHN Nasdaq
- SWKH Nasdaq
- Market Cap
- CHN 153.9M
- SWKH 179.1M
- IPO Year
- CHN N/A
- SWKH 1999
- Fundamental
- Price
- CHN $16.90
- SWKH $14.83
- Analyst Decision
- CHN
- SWKH Strong Buy
- Analyst Count
- CHN 0
- SWKH 1
- Target Price
- CHN N/A
- SWKH $18.00
- AVG Volume (30 Days)
- CHN 31.8K
- SWKH 14.3K
- Earning Date
- CHN 01-01-0001
- SWKH 08-14-2025
- Dividend Yield
- CHN 0.19%
- SWKH N/A
- EPS Growth
- CHN N/A
- SWKH 55.18
- EPS
- CHN N/A
- SWKH 1.41
- Revenue
- CHN N/A
- SWKH $37,409,000.00
- Revenue This Year
- CHN N/A
- SWKH $52.93
- Revenue Next Year
- CHN N/A
- SWKH N/A
- P/E Ratio
- CHN N/A
- SWKH $10.38
- Revenue Growth
- CHN N/A
- SWKH 47.31
- 52 Week Low
- CHN $9.00
- SWKH $12.00
- 52 Week High
- CHN $12.98
- SWKH $16.24
- Technical
- Relative Strength Index (RSI)
- CHN 66.99
- SWKH 54.95
- Support Level
- CHN $16.71
- SWKH $14.38
- Resistance Level
- CHN $17.32
- SWKH $14.84
- Average True Range (ATR)
- CHN 0.26
- SWKH 0.27
- MACD
- CHN 0.01
- SWKH 0.04
- Stochastic Oscillator
- CHN 73.58
- SWKH 98.92
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.